Eli Lilly CDR (CAD Hedged)

California becomes the first state to sell its own brand of generic insulin through the CalRx program, with five-pack insulin pens available for $55 starting January 1, 2025.

Kailera Therapeutics raised $600 million in Series B financing led by Bain Capital Private Equity to advance its obesity treatment pipeline.

Bristol Myers Squibb will present data from over 50 studies at ESMO 2025, including first-in-class results from izalontamab brengitecan (iza-bren), an EGFRxHER3 bispecific ADC that received FDA Breakthrough Therapy designation for EGFR-mutated NSCLC.

Bill Gates and the Pan American Health Organization are exploring ways to make expensive weight-loss drugs like Wegovy and Mounjaro more accessible in lower-income countries where 70% of obese patients live.

Wall Street analysts predict Eli Lilly and AstraZeneca are the most likely pharmaceutical companies to strike the next drug pricing deal with the Trump administration following Pfizer's September 29 agreement.

Evommune filed for a $100 million NYSE IPO to fund Phase 2 trials of EVO756, which targets MRGPRX2 protein on mast cells for chronic spontaneous urticaria treatment.

Peter Marks, former director of the FDA's Center for Biologics Evaluation and Research, has joined Eli Lilly as senior vice president of molecule discovery and head of infectious disease work.

Trogenix completed a $95 million Series A financing led by IQ Capital to advance its Odysseus® platform for potentially curative cancer therapies.

Sitryx Therapeutics received FDA clearance for its IND application for SYX-5219, a first-in-class oral PKM2 modulator targeting atopic dermatitis.

Halozyme Therapeutics has agreed to acquire Elektrofi for $750 million upfront plus up to $150 million in milestone payments, gaining access to breakthrough Hypercon microparticle technology.